Difference between revisions of "Profiles"
Jump to navigation
Jump to search
m |
|||
| (13 intermediate revisions by 2 users not shown) | |||
| Line 19: | Line 19: | ||
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles=== | ===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles=== | ||
| − | * [[Media:QIBA_DWIProfile_Consensus_Dec2019_Final.pdf|Diffusion-Weighted | + | * [[Media:QIBA_DWIProfile_Consensus_Dec2019_Final.pdf| MR Diffusion-Weighted Imaging (DWI) 2019-12-20]] |
| − | *[[Media:QIBA_AmyloidPET_20June2018_consensus.pdf | | + | *[[Media:QIBA_AmyloidPET_20June2018_consensus.pdf | PET F-18 for Amyloid 2018-06-20]] |
*[[Media:MRE-QIBA_Profile-2019-06-06-CONSENSUS-maintenance.pdf | MR Elastography of the Liver 2019-06-06]] | *[[Media:MRE-QIBA_Profile-2019-06-06-CONSENSUS-maintenance.pdf | MR Elastography of the Liver 2019-06-06]] | ||
| − | *[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | SPECT | + | *[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | SPECT Ioflupane for Neurodegenerative Disease v1.1, 2017-06-26]] |
| − | *[[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf | SPECT | + | *[[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf | SPECT Ioflupane for Neurodegenerative Disease v2.0, 2019-10-15]] |
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]] | :*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]] | ||
| Line 33: | Line 33: | ||
*[[Media:DCE-MRI Quantification Profile v1.0.pdf|MR DCE Quantification v1.0 2012-08-08]] | *[[Media:DCE-MRI Quantification Profile v1.0.pdf|MR DCE Quantification v1.0 2012-08-08]] | ||
| − | *[[Media:QIBA_CTA_Profile_as_of_2020-Mar-10.pdf| Atherosclerosis | + | *[[Media:QIBA_CTA_Profile_as_of_2020-Mar-10.pdf| CTA Atherosclerosis 2020-03-10]] |
| − | *[[Media:QIBA_SPECT_99mTC_Profile_10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]] | + | *[[Media:QIBA_SPECT_99mTC_Profile_10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]] |
| Line 42: | Line 42: | ||
'''Please submit comments using the '''[http://tinyurl.com/QIBA-Public-Comment-Form '''online form''']''' | '''Please submit comments using the '''[http://tinyurl.com/QIBA-Public-Comment-Form '''online form''']''' | ||
| − | *[[ | + | *[[Media:QIBA_Profile_MSK-Cartilage-Stage1_Profile.pdf|MR MSK cartilage for joint disease 2020-05-18]] (<font color=##00cc00>'''Open for comment: June 26, 2020 - September 29, 2020'''</font>) |
| − | *[[Media:QIBA_DSC-MRI_Stage1_Profile.pdf|Dynamic Susceptibility Contrast | + | *[[Media:QIBA_DSC-MRI_Stage1_Profile.pdf|MR Dynamic Susceptibility Contrast (DSC-MRI) 2020-01-29]] ('''closed''' on May 15, 2020) |
| − | *[[Media:QIBA_US_SWS_Profile_10.21.19.pdf| | + | *[[Media:QIBA_US_SWS_Profile_10.21.19.pdf|US Shear Wave Speed for Liver Fibrosis 2019-10-21]] ('''closed''' on December 18, 2019) |
| − | :*[[Media:SWS Checklists-Appendix E.xlsx|Appendix E: | + | :*[[Media:SWS Checklists-Appendix E.xlsx|Appendix E: SWS Checklists, 2019-10-21]] ('''closed''' on December 18, 2019) |
| − | *[[Media:QIBA_CT_Lung_Density_Profile_090319-clean.pdf | | + | *[[Media:QIBA_CT_Lung_Density_Profile_090319-clean.pdf | CT Lung Density 2019-09-03]] (Contains Conformance Checklist, Appendix B) ('''closed''' on October 16, 2019) |
| − | :*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx| | + | :*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Appendix E:CT Lung Density Protocols 2019-06-26]] ('''closed''' on October 16, 2019) |
| − | *[[Media:QIBA_fMRI_Profile_1_PC-rev1.pdf| | + | *[[Media:QIBA_fMRI_Profile_1_PC-rev1.pdf| fMRI for Sensorimotor Mapping 2017-06-19]] ('''closed''' on December 31, 2017) |
'''[[Comment Resolutions]]''' <font color=black>are posted for '''Past Public Comments''' and '''Past Technical Confirmations'''.<font> | '''[[Comment Resolutions]]''' <font color=black>are posted for '''Past Public Comments''' and '''Past Technical Confirmations'''.<font> | ||
| − | ==Format for Citing Profiles== | + | |
| + | ====Format for Citing Profiles==== | ||
Cite QIBA Profile documents as: | Cite QIBA Profile documents as: | ||
| − | : ''Specific QIBA Biomarker Committee. Specific Profile Title'', Quantitative Imaging Biomarkers Alliance. ''Version. Profile Stage''. | + | : ''Specific QIBA Biomarker Committee. Specific Profile Title'', Quantitative Imaging Biomarkers Alliance. ''Version. Profile Stage''. ''Date''. Available from: ''URL'' |
Example: | Example: | ||
| − | : QIBA | + | : QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles |
| − | + | ====Statements of Endorsement==== | |
| − | ==Statements of Endorsement== | ||
*[[Industry]] | *[[Industry]] | ||
*[[Clinical Sites]] | *[[Clinical Sites]] | ||
*[[Additional letters of support can be found here]] | *[[Additional letters of support can be found here]] | ||
| − | + | ====See Also==== | |
| − | ==See Also== | ||
*[[How to use QIBA Profiles]] | *[[How to use QIBA Profiles]] | ||
*[[Committees|Biomarker Committee]] pages may also have links to DRAFT Profile documents for the next Stage. | *[[Committees|Biomarker Committee]] pages may also have links to DRAFT Profile documents for the next Stage. | ||
Revision as of 00:04, 8 July 2020
Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.
Profiles may be of use at any Stage.
Stage 3: Technically Confirmed Profiles
- Conformance Checklists (refer to Appendix C in the Profile document - pg 42)
- Assessment Procedures (refer to Section 4 in the Profile document - pg 30)
Stage 2: Consensus Profiles
Stage 1: Public Comment Profiles
Please submit comments using the online form
- MR MSK cartilage for joint disease 2020-05-18 (Open for comment: June 26, 2020 - September 29, 2020)
- MR Dynamic Susceptibility Contrast (DSC-MRI) 2020-01-29 (closed on May 15, 2020)
- US Shear Wave Speed for Liver Fibrosis 2019-10-21 (closed on December 18, 2019)
- Appendix E: SWS Checklists, 2019-10-21 (closed on December 18, 2019)
- CT Lung Density 2019-09-03 (Contains Conformance Checklist, Appendix B) (closed on October 16, 2019)
- Appendix E:CT Lung Density Protocols 2019-06-26 (closed on October 16, 2019)
- fMRI for Sensorimotor Mapping 2017-06-19 (closed on December 31, 2017)
Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations.
Format for Citing Profiles
Cite QIBA Profile documents as:
- Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Version. Profile Stage. Date. Available from: URL
Example:
- QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles
Statements of Endorsement
See Also
- How to use QIBA Profiles
- Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
- Profile Conformance describes how sites and products claim conformance to a Profile.
- QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)